Coronary artery disease - drug-eluting stents: review decision - June 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix A: decision paper presented to the Institute's Guidance Executive
-
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 120 KB)
-
Coronary artery disease - drug-eluting stents: Review Proposal - April 2014 information
-
Appendix A - matrix of stakeholders
-
-
Appendix B - GE proposal paper - April 2014
-
-
Coronary artery disease - drug-eluting stents: review decision - October 2010 information
-
Coronary artery disease - drug-eluting stents: appendix A decision paper considered by the Institute's Guidance Executive
-
-
-
TA152 Coronary artery disease - drug-eluting stents: review proposal August 2010 information
-
Appendix A: Matrix of stakeholders
-
-
Appendix B: Proposal paper presented to the Institute's Guidance Executive
-
-
TA152 Coronary artery disease - drug-eluting stents: appendix A provisional matrix of stakeholders
-
-
TA152 Coronary artery disease - drug-eluting stents: appendix B proposal paper presented to the Institute's Guidance Executive
-
-
Review Decision - July 2009: Appendix 1: Proposal comment summary table
-
Review Decision - July 2009: Appendix 1: Proposal comment summary table (PDF 43 KB)
-
-
A link to the summary of the responses from this consultation.
-
Review Decision - July 2009: Appendix 1: Proposal comment summary table (PDF 43 KB)
-
-
Review proposal - May 2009: appendix A, provisional matrix
-
Review proposal - May 2009: appendix A, provisional matrix (PDF 33 KB)
Coronary artery disease - drug-eluting stents (part review of TA71): appeal
-
Coronary artery disease - drug-eluting stents (part review of TA71): appeal information
-
Ischaemic heart disease - coronary artery stents (review): Appeal information
-
Ischaemic heart disease - coronary artery stents (review): Appeal announcement information
-
Ischaemic heart disease - coronary artery stents (review): Appeals received from Cordis 1
-
-
Ischaemic heart disease - coronary artery stents (review): Appeals received from Cordis 2
-
-
Ischaemic heart disease - coronary artery stents (review): Appeals received from Cordis 3
-
-
Ischaemic heart disease - coronary artery stents: appeal decision
-
Ischaemic heart disease - coronary artery stents: appeal decision (PDF 40 KB)
Ischaemic heart disease - coronary artery stents (review): Final Appraisal Determination (FAD)
-
-
Ischaemic heart disease - coronary artery stents (review): Final appraisal determination
-
-
Ischaemic heart disease - coronary artery stents (review): Addendum 7
-
Ischaemic heart disease - coronary artery stents (review): Addendum 7 (PDF 70 KB)
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
Ischaemic heart disease - coronary artery stents (review): Response to public comments on the ACD
-
-
Response to Consultee and Commentator comments on the ACD
-
Response to Consultee and Commentator comments on the ACD (PDF 573 KB)
-
Consultee and commentator comments on the ACD
-
Abbott Laboratories Ltd
-
-
Action Heart
-
-
Boston Scientific
-
-
British Cardiovascular Industry Association
-
-
British Cardiovascular Society and British Cardiovascular Intervention Society
-
British Cardiovascular Society and British Cardiovascular Intervention Society (PDF 37 KB)
-
Cordis Corporation
-
-
Department of Health
-
-
Department of Health, Social Services and Public Safety for Northern Ireland
-
Department of Health, Social Services and Public Safety for Northern Ireland (PDF 16 KB)
-
Kiwimed
-
-
Medtronic AVE
-
-
NHS Quality Improvement Scotland
-
-
Royal College of Nursing
-
-
NHS Supply Chain
-
-
Consultee and Commentator comments on the spreadsheets for agenda 5 and 6
-
Ischaemic heart disease - coronary artery stents (review): comments
-
Ischaemic heart disease - coronary artery stents (review): comments (PDF 165 KB)
-
Abbott Laboratories Ltd
-
-
Boston Scientific
-
-
British Cardiovascular Industry Association
-
-
British Cardiovascular Society and British Cardiovascular Intervention Society
-
British Cardiovascular Society and British Cardiovascular Intervention Society (PDF 37 KB)
-
Cordis Corporation
-
-
Medtronic AVE
-
-
Expert comments on the ACD
-
Clark
-
-
Bishop
-
Ischaemic heart disease - coronary artery stents (review): appraisal consultation
-
Ischaemic heart disease - coronary artery stents (review): appraisal consultation
-
Ischaemic heart disease - coronary artery stents (review): Consultees/Commentators information
-
-
Evaluation report
-
Overview
-
-
Coronary artery disease - drug-eluting stents: assessment report
-
Coronary artery disease - drug-eluting stents: assessment report (PDF 1 MB)
-
Consultee and commentator comments on the assessment report
-
Association of British Health Care Industries (support letter)
-
Association of British Health Care Industries (support letter) (PDF 34 KB)
-
Boston Scientific Ltd
-
-
British Cardiac Society and British Cardiovascular Intervention Society (joint response)
-
British Cardiac Society and British Cardiovascular Intervention Society (joint response) (PDF 47 KB)
-
British Cardiovascular Industry Association
-
-
Cordis UK
-
-
Department of Health
-
-
EUCOMED
-
-
Kiwimed Ltd
-
-
Guidant Ltd
-
-
Medtronic Ltd
-
-
NHS Quality Improvement Scotland
-
-
Royal College of Nursing
-
-
Royal College of Physicians
-
-
Royal College of Physicians of Edinburgh
-
-
Society of Cardiothoracic Surgeons of GB and Ireland
-
Society of Cardiothoracic Surgeons of GB and Ireland (PDF 35 KB)
-
Non-manufacturer submissions
-
British Cardiac Society and British Cardiovascular Intervention Society
-
British Cardiac Society and British Cardiovascular Intervention Society (PDF 47 KB)
-
Royal College of Physicians of Edinburgh
-
-
Manufacturer submissions (executive summary only)
-
Biosensors Europe
-
-
Biotronik UK Ltd
-
-
Boston Scientific Ltd
-
-
Cordis UK
-
-
Guidant Ltd
-
-
Kiwimed Ltd
-
-
Medtronic Ltd
-
-
Sorin Group UK Ltd
-
-
Expert written personal statements
-
Dr A H Gershlick, Consultant Cardiologist, Glenfield Hospital NHS Trust - nominated as a clinical expert by British Heart Foundation and British Cardiac Society
-
-
Mr Ron Box - nominated as a patient representative by Heart Care Partnership
-
Mr Ron Box - nominated as a patient representative by Heart Care Partnership (PDF 27 KB)
-
Rev Dan Paterson, Retired Methodist Minister - nominated as a patient representative by Heart Care Partnership
-
-
Dr Martyn Thomas, President, British Cardiovascular Intervention Society - nominated as a clinical expert by British Cardiac Society, British Cardiovascular Intervention Society and Royal College of Physicians
-
-
Mrs Jill Bishop, Cardiac Catherter Lab Manager, British Association for Nursing in Cardiac Care - nominated as a clinical expert by British Association for Nursing in Cardiac Care
-
-
Dr Keith Oldroyd, Consultant Cardiologist, Western Infirmary - nominated as a clinical expert by NHS Quality Improvement Scotland
-
-
Mrs Liz Clark - nominated as a patient expert by the Heart Care Partnership
-
Mrs Liz Clark - nominated as a patient expert by the Heart Care Partnership (PDF 14 KB)
-
Additional work specification I
-
-
Additional work I (3' addendum)
-
-
Comments received from consultees and commentators on additional work I (3' addendum)
-
Boston Scientific Ltd
-
-
British Cardiovascular Industry Association
-
-
British Cardiac Society and British Cardiovascular Intervention Society (joint submission)
-
-
Cordis Corporation
-
-
Guidant Corporation
-
-
Medtronic
-
-
The Royal College of Physicians
-
-
The Royal College of Physicians Edinburgh
-
-
Additional sensitivity analyses post additional work (3? addendum supplement)
-
Additional sensitivity analyses post additional work (3? addendum supplement) (PDF 211 KB)
-
Additional work specification II (following FDA recommendations)
-
Additional work specification II (following FDA recommendations) (PDF 25 KB)
-
Additional sensitivity analyses (4' addendum - including clopidogrel costs)
-
Additional sensitivity analyses (4' addendum - including clopidogrel costs) (PDF 77 KB)
-
Comments received from consultees and commentators on additional sensitivity analyses (post additional work [3?] and including clopidogrel costs [4'])
-
Abbott Vascular UK
-
-
Boston Scientific Ltd
-
-
Cordis Corporation
-
-
Department of Health
-
-
Medtronic AVE
-
-
Action Heart
-
-
British Cardiovascular Industry Association
-
-
British Cardiac Society and British Cardiovascular Intervention Society (joint submission)
-
-
The Royal College of Physicians
-
-
Additional sensitivity analyses (5' addendum - taking account ACS patients)
-
Additional sensitivity analyses (5' addendum - taking account ACS patients) (PDF 79 KB)
-
Addendum 6 (Sensitivity Analysis Tables for Drug-Eluting Stent Appraisal including Additional Use of Clopidogrel)
-
Ischaemic heart disease - coronary artery stents (review):Clarification of Addendum 6
-
Ischaemic heart disease - coronary artery stents (review):Clarification of Addendum 6
-
Ischaemic heart disease - coronary artery stents (review):Clarification of Addendum 6 (PDF 22 KB)
Project specification form
-
Project specification form
-
Final protocol
-
Final protocol
-
Final scope - Ischaemic heart disease - coronary artery stents (review)
-
Final scope - Ischaemic heart disease - coronary artery stents (review)
-
Final scope - Ischaemic heart disease - coronary artery stents (review) (PDF 95 KB)
Summary of consultee and commentator comments on the draft scope
-
Summary of consultee and commentator comments on the draft scope
-
Summary of consultee and commentator comments on the draft scope (PDF 183 KB)
Summary of consultee and commentator comments on the draft matrix
-
Summary of consultee and commentator comments on the draft matrix
-
Summary of consultee and commentator comments on the draft matrix (PDF 100 KB)
Archive: Provisional matrix of consultees and commentators
-
Archive: Provisional matrix of consultees and commentators
-
Archive: Provisional matrix of consultees and commentators (PDF 29 KB)